top of page
Executive Spotlights

BioMarin Appoints Alexander Hardy President and CEO

San Rafael, CA, November 1, 2023 (PRNewswire) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), today announced the appointment of Alexander Hardy as its new president and chief executive officer, effective December 1, 2023. Mr. Hardy, who is currently the CEO of Genentech, will also join BioMarin’s board of directors bringing his over 30 years of experience in global healthcare and biotechnology industries. Jean-Jacques Bienaimé, the outgoing chairman and CEO, will retire after leading the company for 18 years. Richard A. Meier, BioMarin’s lead independent director, will take over as chair of the board of directors.

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page